KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Amortization of Deferred Charges (2017 - 2026)

Aquestive Therapeutics has reported Amortization of Deferred Charges over the past 9 years, most recently at $10.8 million for Q4 2025.

  • For Q4 2025, Amortization of Deferred Charges rose 239.02% year-over-year to $10.8 million; the TTM value through Dec 2025 reached $11.0 million, up 4558.9%, while the annual FY2025 figure was $11.0 million, 4558.9% up from the prior year.
  • Amortization of Deferred Charges for Q4 2025 was $10.8 million at Aquestive Therapeutics, up from -$5.3 million in the prior quarter.
  • Over five years, Amortization of Deferred Charges peaked at $10.8 million in Q4 2025 and troughed at -$7.8 million in Q4 2024.
  • A 5-year average of $800578.9 and a median of $220000.0 in 2023 define the central range for Amortization of Deferred Charges.
  • Biggest five-year swings in Amortization of Deferred Charges: soared 89000.0% in 2024 and later tumbled 298.92% in 2025.
  • Year by year, Amortization of Deferred Charges stood at $127000.0 in 2021, then crashed by 54.33% to $58000.0 in 2022, then crashed by 94.83% to $3000.0 in 2023, then tumbled by 259400.0% to -$7.8 million in 2024, then surged by 239.02% to $10.8 million in 2025.
  • Business Quant data shows Amortization of Deferred Charges for AQST at $10.8 million in Q4 2025, -$5.3 million in Q3 2025, and $2.7 million in Q2 2025.